Chaperoning osteogenesis: New protein-folding disease paradigms

Trends in Cell Biology

Volumn 21, Issue 3, 2011, Pages 168-176

  Makareeva, Elena ^a   Aviles, Nydea A ^a   Leikin, Sergey ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CALNEXIN; CALRETICULIN; CHAPERONE; COLLAGEN; COLLAGEN TYPE 1; HEAT SHOCK PROTEIN 47; PROCOLLAGEN; PROCOLLAGEN LYSINE 2 OXOGLUTARATE 5 DIOXYGENASE; PROTEIN;

AMINO TERMINAL SEQUENCE; BONE DEVELOPMENT; CARBOXY TERMINAL SEQUENCE; CELL; CHONDRODYSPLASIA; EHLERS DANLOS SYNDROME; ENDOPLASMIC RETICULUM STRESS; GENE MUTATION; HUMAN; ISOMERIZATION; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FOLDING; REVIEW; UNFOLDED PROTEIN RESPONSE;

ANIMALS; COLLAGEN; HUMANS; MOLECULAR CHAPERONES; OSTEOGENESIS; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES; STRESS, PHYSIOLOGICAL;

VERTEBRATA;

EID: 79952105767     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2010.11.007     Document Type: Review

References (87)

1. Karsenty G., et al. Genetic control of bone formation. Annu. Rev. Cell Dev. Biol. 2009, 25:629-648.
2. Matsuo K. Cross-talk among bone cells. Curr. Opin. Nephrol. Hypertens. 2009, 18:292-297.
3. Confavreux C.B., et al. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol. Cell Endocrinol. 2009, 310:21-29.
4. Marini J.C. Osteogenesis imperfecta. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 2008, 446-450. ASBMR. 7th edn. C.J. Rosen (Ed.).
5. Marini J.C., et al. Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta. Cell Tissue Res. 2010, 339:59-70.
6. Morello R., et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006, 127:291-304.
7. Barnes A.M., et al. Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta. N. Engl. J. Med. 2006, 355:2757-2764.
8. Cabral W.A., et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat. Genet. 2007, 39:359-365.
9. Choi J.W., et al. Severe osteogenesis imperfecta in cyclophilin B-deficient mice. PLoS Genet. 2009, 5:e1000750.
10. van Dijk F.S., et al. PPIB mutations cause severe osteogenesis imperfecta. Am. J. Hum. Genet. 2009, 85:521-527.
11. Barnes A.M., et al. Lack of cyclophilin B in osteogenesis imperfecta with normal collagen folding. N. Engl. J. Med. 2010, 362:521-528.
12. Alanay Y., et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am. J. Hum. Genet. 2010, 86:551-559.
13. Drogemuller C., et al. A missense mutation in the SERPINH1 gene in Dachshunds with osteogenesis imperfecta. PLoS Genet. 2009, 5:e1000579.
14. Christiansen H.E., et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. Am. J. Hum. Genet. 2010, 86:389-398.
15. Shaheen R., et al. FKBP10 and Bruck syndrome: phenotypic heterogeneity or call for reclassification?. Am. J. Hum. Genet. 2010, 87:306-307. Erratum 571.
16. Kelley, B.P. et al. (2010) Mutations in FKBP10 cause recessive osteogenesis imperfecta and type 1 bruck syndrome. J. Bone. Miner Res., In press. doi:10.1002/jbmr.250.
17. Hartl F.U., Hayer-Hartl M. Converging concepts of protein folding in vitro and in vivo. Nat. Struct. Mol. Biol. 2009, 16:574-581.
18. Saibil H.R. Chaperone machines in action. Curr. Opin. Struct. Biol. 2008, 18:35-42.
19. Cali T., et al. The endoplasmic reticulum: crossroads for newly synthesized polypeptide chains. Prog. Mol. Biol. Transl. Sci. 2008, 83:135-179.
20. Koide T., et al. Specific recognition of the collagen triple helix by chaperone HSP47. II. The HSP47-binding structural motif in collagens and related proteins. J. Biol. Chem. 2006, 281:11177-11185.
21. Koide T., et al. Specific recognition of the collagen triple helix by chaperone HSP47: minimal structural requirement and spatial molecular orientation. J. Biol. Chem. 2006, 281:3432-3438.
22. Ishida Y., et al. Type I collagen in Hsp47-null cells is aggregated in endoplasmic reticulum and deficient in N-propeptide processing and fibrillogenesis. Mol. Biol. Cell 2006, 17:2346-2355.
23. Ishida Y., et al. Autophagic elimination of misfolded procollagen aggregates in the endoplasmic reticulum as a means of cell protection. Mol. Biol. Cell 2009, 20:2744-2754.
24. Anfinsen C.B. Principles that govern the folding of protein chains. Science 1973, 181:223-230.
25. Sanchez-Ruiz J.M. Protein kinetic stability. Biophys. Chem. 2010, 148:1-15.
26. Whisstock J.C., Bottomley S.P. Molecular gymnastics: serpin structure, folding and misfolding. Curr. Opin. Struct. Biol. 2006, 16:761-768.
27. Ramirez-Alvarado M. Principles of protein misfolding. Prog. Mol. Biol. Transl. Sci. 2008, 84:115-160.
28. Moore R.A., et al. Prion protein misfolding and disease. Curr. Opin. Struct. Biol. 2009, 19:14-22.
29. Sohl J.L., et al. Unfolded conformations of alpha-lytic protease are more stable than its native state. Nature 1998, 395:817-819.
30. Clark P.L. Protein folding in the cell: reshaping the folding funnel. Trends Biochem. Sci. 2004, 29:527-534.
31. Englander S.W., et al. Protein folding and misfolding: mechanism and principles. Q. Rev. Biophys. 2007, 40:287-326.
32. Dill K.A., et al. The protein folding problem. Annu. Rev. Biophys. 2008, 37:289-316.
33. Canty E.G., Kadler K.E. Procollagen trafficking, processing and fibrillogenesis. J. Cell Sci. 2005, 118:1341-1353.
34. Koide, T. and Nagata, K. (2005) Collagen biosynthesis. In Collagen, pp. 85-114, Springer-Verlag.
35. Engel, J. and Bachinger, H.P. (2005) Structure, stability and folding of the collagen triple helix. In Collagen, pp. 7-33, Springer-Verlag.
36. Leikina E., et al. Type I collagen is thermally unstable at body temperature. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1314-1318.
37. Makareeva E., Leikin S. Procollagen triple helix assembly: an unconventional chaperone-assisted folding paradigm. PLoS One 2007, 2:e1029.
38. Makareeva E., et al. Structural heterogeneity of type I collagen triple helix and its role in osteogenesis imperfecta. J. Biol. Chem. 2008, 283:4787-4798.
39. Makareeva E., et al. Molecular mechanism of alpha 1(I)-osteogenesis imperfecta/Ehlers-Danlos syndrome: unfolding of an N-anchor domain at the N-terminal end of the type I collagen triple helix. J. Biol. Chem. 2006, 281:6463-6470.
40. Myllyharju J. Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. Ann. Med. 2008, 40:402-417.
41. Gorres K.L., Raines R.T. Prolyl 4-hydroxylase. Crit. Rev. Biochem. Mol. Biol. 2010, 45:106-124.
42. Nagata K. HSP47 as a collagen-specific molecular chaperone: function and expression in normal mouse development. Semin. Cell Dev. Biol. 2003, 14:275-282.
43. Nagai N., et al. Embryonic lethality of molecular chaperone hsp47 knockout mice is associated with defects in collagen biosynthesis. J. Cell Biol. 2000, 150:1499-1506.
44. Ishikawa Y., et al. The rough endoplasmic reticulum-resident FK506-binding protein FKBP65 is a molecular chaperone that interacts with collagens. J. Biol. Chem. 2008, 283:31584-31590.
45. Raghunath M., et al. Delayed triple helix formation of mutant collagen from patients with osteogenesis imperfecta. J. Mol. Biol. 1994, 236:940-949.
46. Hyry M., et al. Missense mutations that cause Bruck syndrome affect enzymatic activity, folding, and oligomerization of lysyl hydroxylase 2. J. Biol. Chem. 2009, 284:30917-30924.
47. Vranka J.A., et al. Prolyl 3-hydroxylase 1, enzyme characterization and identification of a novel family of enzymes. J. Biol. Chem. 2004, 279:23615-23621.
48. Ishikawa Y., et al. Biochemical characterization of the prolyl 3-hydroxylase 1.cartilage-associated protein.cyclophilin B complex. J. Biol. Chem. 2009, 284:17641-17647.
49. Chang W., et al. Prolyl 3-hydroxylase 1 and CRTAP are mutually stabilizing in the endoplasmic reticulum collagen prolyl 3-hydroxylation complex. Hum. Mol. Genet. 2010, 19:223-234.
50. Mizuno K., et al. Effect of the -Gly-3(S)-hydroxyprolyl-4(R)-hydroxyprolyl- tripeptide unit on the stability of collagen model peptides. FEBS J. 2008, 275:5830-5840.
51. Weis M.A., et al. Location of 3-hydroxyproline residues in collagen types I, II, III, and V/XI implies a role in fibril supramolecular assembly. J. Biol. Chem. 2010, 285:2580-2590.
52. Smith T., et al. Hsp47 and cyclophilin B traverse the endoplasmic reticulum with procollagen into pre-Golgi intermediate vesicles. A role for Hsp47 and cyclophilin B in the export of procollagen from the endoplasmic reticulum. J. Biol. Chem. 1995, 270:18323-18328.
53. Steinmann B., et al. Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase. J. Biol. Chem. 1991, 266:1299-1303.
54. Schwarze, U. et al. (2009) Mutations in PPIB, which encodes a prolyl cis-trans isomerase (cyclophilin B), in recessive forms of osteogenesis imperfecta (OI). In Program and Abstracts of the 59th Annual Meeting of the American Society of Human Genetics, Honolulu, October 20-24 http://www.ashg.org/2009meeting/pdf/platforms_4up.pdf.
55. Barnes A.M., et al. Osteogenesis imperfecta, normal collagen folding, and lack of cyclophilin B. N. Engl. J. Med. 2010, 362:1941-1942.
56. Lisse T.S., et al. ER stress-mediated apoptosis in a new mouse model of osteogenesis imperfecta. PLoS Genet. 2008, 4:e7.
57. Forlino A., et al. Selective retention and degradation of molecules with a single mutant alpha1(I) chain in the Brtl IV mouse model of OI. Matrix Biol. 2007, 26:604-614.
58. Malhotra J.D., Kaufman R.J. The endoplasmic reticulum and the unfolded protein response. Semin. Cell Dev. Biol. 2007, 18:716-731.
59. Rutkowski D.T., Hegde R.S. Regulation of basal cellular physiology by the homeostatic unfolded protein response. J. Cell Biol. 2010, 189:783-794.
60. Chessler S.D., Byers P.H. BiP binds type I procollagen pro alpha chains with mutations in the carboxyl-terminal propeptide synthesized by cells from patients with osteogenesis imperfecta. J. Biol. Chem. 1993, 268:18226-18233.
61. Forlino A., et al. Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics 2007, 7:1877-1891.
62. 1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies. Clin. Sci. (Lond.) 2009, 116:837-850.
63. Gotkin M.G., et al. Intracellular trafficking and degradation of unassociated proalpha2 chains of collagen type I. Exp. Cell Res. 2004, 296:307-316.
64. Hamamura K., Yokota H. Stress to endoplasmic reticulum of mouse osteoblasts induces apoptosis and transcriptional activation for bone remodeling. FEBS Lett. 2007, 581:1769-1774.
65. Murakami T., et al. Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formation. Nat. Cell Biol. 2009, 11:1205-1211.
66. Bateman J.F., et al. Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations. Nat. Rev. Genet. 2009, 10:173-183.
67. Wu J., Kaufman R.J. From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ. 2006, 13:374-384.
68. Rauch F., Glorieux F.H. Osteogenesis imperfecta. Lancet 2004, 363:1377-1385.
69. Uveges T.E., et al. Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. J. Bone Miner Res. 2008, 23:1983-1994.
70. Zhang P., et al. The PERK eukaryotic initiation factor 2α kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol. Cell Biol. 2002, 22:3864-3874.
71. Sohaskey M.L., et al. Osteopotentia regulates osteoblast maturation, bone formation, and skeletal integrity in mice. J. Cell Biol. 2010, 189:511-525.
72. Lapunzina P., et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am. J. Hum. Genet. 2010, 87:110-114.
73. Yadav V.K., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837.
74. Mason J.J., Williams B.O. SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease. J. Osteoporos. 2010, article ID 460120 (9 pages).
75. Marini J.C., et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum. Mutat. 2007, 28:209-221.
76. Cabral W.A., et al. Mutations near amino end of alpha1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing. J. Biol. Chem. 2005, 280:19259-19269.
77. Rajpar M.H., et al. Targeted induction of endoplasmic reticulum stress induces cartilage pathology. PLoS Genet. 2009, 5:e1000691.
78. Kwan K.M., et al. Abnormal compartmentalization of cartilage matrix components in mice lacking collagen X: implications for function. J. Cell Biol. 1997, 136:459-471.
79. Boot-Handford R.P., Briggs M.D. The unfolded protein response and its relevance to connective tissue diseases. Cell Tissue Res. 2010, 339:197-211.
80. Tsang K.Y., et al. In vivo cellular adaptation to ER stress: survival strategies with double-edged consequences. J. Cell Sci. 2010, 123:2145-2154.
81. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
82. Yoshida H. ER stress and diseases. FEBS J. 2007, 274:630-658.
83. Anderson D.E., et al. α-Lytic protease precursor: characterization of a structured folding intermediate. Biochemistry 1999, 38:4728-4735.
84. Chen Y.J., Inouye M. The intramolecular chaperone-mediated protein folding. Curr. Opin. Struct. Biol. 2008, 18:765-770.
85. Hidvegi T., et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010, 329:229-232.
86. Schonthal A.H. Endoplasmic reticulum stress and autophagy as targets for cancer therapy. Cancer Lett. 2009, 275:163-169.
87. Bachinger H.P. The influence of peptidyl-prolyl cis-trans isomerase on the in vitro folding of type III collagen. J. Biol. Chem. 1987, 262:17144-17148.